Your browser doesn't support javascript.
loading
Embracing Imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19.
Kow, Chia Siang; Ramachandram, Dinesh Sangarran; Hasan, Syed Shahzad.
Afiliação
  • Kow CS; School of Pharmacy, International Medical University, 126, Jalan Jalil Perkasa, Bukit Jalil, Kuala Lumpur, Malaysia. chiasiang_93@hotmail.com.
  • Ramachandram DS; School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.
  • Hasan SS; School of Applied Sciences, University of Huddersfield, Huddersfield, UK.
Angiogenesis ; 26(4): 481-483, 2023 11.
Article em En | MEDLINE | ID: mdl-37530975
Imatinib, an ABL tyrosine-kinase inhibitor, shows promise in restoring endothelial barrier function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar compartment to the systemic compartment. COVID-19 is characterized by an alveolar cytokine storm, and imatinib has been shown to strengthen the endothelial barrier and mitigate alveolar inflammatory responses by modulating NF-κB signaling. Incorporating imatinib into COVID-19 treatment strategies offers a novel approach to safeguard the endothelial barrier and address the complex pathophysiology of the disease, including its potential implications in long COVID. Given that endothelial dysfunction plays a central role in COVID-19 progression and long COVID development, protecting the endothelial barrier during acute infection is crucial in preventing the persistent endothelial dysfunction associated with long COVID.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Síndrome de COVID-19 Pós-Aguda Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Síndrome de COVID-19 Pós-Aguda Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article